Stenobird

Episode

The Brain’s Redox Crisis: NAD, Mitochondria, and the Next Wave of Neuropsychiatric Treatment

Podcast
The Energy Code
Published
Apr 24, 2026
Duration seconds
1128
Processing state
processed
Canonical source
https://theenergycode.podbean.com/e/the-brain-s-redox-crisis-nad-mitochondria-and-the-next-wave-of-neuropsychiatric-treatment/
Audio
https://mcdn.podbean.com/mf/web/fewvmznt4upi7iwj/redox_mixdown.mp3
JSON
/v1/public/podcasts/the-energy-code-2136601/episodes/the-brain-s-redox-crisis-nad-mitochondria-and-the-next-wave-of-neuropsychiatric-treatment
Markdown
/podcast/the-energy-code-2136601/the-brain-s-redox-crisis-nad-mitochondria-and-the-next-wave-of-neuropsychiatric-treatment.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-energy-code-2136601/episodes/the-brain-s-redox-crisis-nad-mitochondria-and-the-next-wave-of-neuropsychiatric-treatment/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-energy-code-2136601/the-brain-s-redox-crisis-nad-mitochondria-and-the-next-wave-of-neuropsychiatric-treatment.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Neuropsychiatric and neurodegenerative diseases may share a common underlying pathology: a breakdown in the brain's redox balance. This deep dive explores how disruptions in the NAD+/NADH ratio drive mitochondrial failure and inflammation across diverse diagnoses.

Topics

  • Neuropsychiatry
  • Mitochondrial Dysfunction
  • NAD+
  • Redox Signaling
  • Alzheimer's Disease
  • Schizophrenia
  • Ketogenic Therapy
  • Bioenergetics
  • Biomarker Development

Highlights

  • Main idea: Redox dysregulation, specifically the NAD+/NADH ratio, acts as a shared organizing principle for both neurodegeneration and psychiatric illness
  • Failure mode: Raising NAD levels in the blood does not guarantee the correction of compartmentalized redox failure within specific brain cells
  • Practical takeaway: Ketogenic therapy may offer benefits beyond alternative fuel by actively modulating the NAD+/NADH redox state
  • Critical bottleneck: The field lacks robust in vivo biomarkers to prove that redox-based therapies are actually engaging their targets in the brain
  • Future direction: Effective treatment must shift from broad supplementation to mechanism-driven, precision interventions based on metabolic signatures

Chapters

  1. 1:00 Redox Failure as a Shared Pathology: An introduction to the thesis that brain disorders are fundamentally issues of redox and bioenergetic failure.
  2. 2:00 The NAD+/NADH Ratio: Defining redox balance through the lens of metabolic control and mitochondrial efficiency.
  3. 4:00 Beyond Protein Aggregation: Why targeting amyloid and tau has failed and why we must look toward mitochondrial stress.
  4. 5:00 Psychiatric Implications: How schizophrenia and bipolar disorder exhibit similar energetic vulnerabilities to neurodegenerative diseases.
  5. 6:00 Targeting NAD+: The potential and the specific molecular importance of NAD in restoring cellular function.
  6. 8:00 The Compartmentalization Problem: The challenge of ensuring therapies reach the cytosol, mitochondria, and nucleus effectively.
  7. 9:00 The Need for Biomarkers: Why measurement and target engagement are more critical to the field than new supplements.
  8. 10:00 Ketogenic Redox Modulation: How ketogenic interventions influence the redox state and improve metabolic flexibility.